AI Engines For more Details: Perplexity Kagi Labs You
Nausea and Vomiting: Prochlorperazine dimaleate is an antipsychotic medication with antiemetic properties. It acts on dopamine receptors in the brain, particularly in the chemoreceptor trigger zone (CTZ), to suppress nausea and vomiting. It is commonly prescribed for various conditions that cause nausea and vomiting, such as motion sickness, vertigo, migraines, chemotherapy, and postoperative nausea and vomiting.
Motion Sickness: Prochlorperazine dimaleate is effective in preventing and treating motion sickness, a common condition characterized by nausea, vomiting, and dizziness during travel, especially in cars, boats, or airplanes. It works by blocking dopamine receptors in the brain, thereby reducing the signals that trigger motion sickness symptoms.
Vertigo: Prochlorperazine dimaleate is used to alleviate symptoms of vertigo, including dizziness, spinning sensations, and imbalance. It helps stabilize the inner ear's vestibular system and reduces the sensation of motion that contributes to vertigo.
Migraine-associated Nausea and Vomiting: Prochlorperazine dimaleate is often prescribed as an adjunct therapy for migraine headaches, particularly to alleviate associated nausea and vomiting. It can provide relief from migraine symptoms and improve the tolerability of other migraine medications.
Psychotic Disorders: Prochlorperazine dimaleate belongs to the class of typical antipsychotic medications, although it is less commonly used for this indication today. It may be prescribed to manage psychotic disorders such as schizophrenia and bipolar disorder, but other antipsychotic drugs are more commonly used due to their improved side effect profiles.
Side Effects: Common side effects of prochlorperazine dimaleate may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. Less commonly, it may cause extrapyramidal symptoms such as tremors, muscle stiffness, and tardive dyskinesia, particularly with long-term use or at higher doses.
Contraindications: Prochlorperazine dimaleate is contraindicated in individuals with a history of hypersensitivity to the medication, severe central nervous system depression, and comatose states. It should be used with caution in elderly patients and those with cardiovascular disease, as it may cause hypotension and arrhythmias.
Drug Interactions: Prochlorperazine dimaleate may interact with other medications, including central nervous system depressants, anticholinergic drugs, and certain antibiotics and antidepressants. Concurrent use of prochlorperazine with these medications may potentiate sedative effects and increase the risk of side effects.
Dosage and Administration: Prochlorperazine dimaleate is available in various formulations, including tablets, oral disintegrating tablets, and injectable solutions. The dosage and administration route depend on the individual's condition, age, and response to treatment. It is important to follow the prescribed dosage and frequency as directed by a healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 2.7 | 0.3 | 8 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 0.9 | 2.44 |
| Allergies | 6.6 | 2.4 | 1.75 |
| Allergy to milk products | 1.6 | 1.3 | 0.23 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.4 | 6.2 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 0.6 | 3.83 |
| Ankylosing spondylitis | 4.2 | 1.5 | 1.8 |
| Anorexia Nervosa | 1.1 | 2.9 | -1.64 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 4.5 | 1.1 | 3.09 |
| Atherosclerosis | 2 | 2.4 | -0.2 |
| Atrial fibrillation | 3.2 | 2.8 | 0.14 |
| Autism | 8.2 | 8.7 | -0.06 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 1.8 | 0.8 | 1.25 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 1.5 | 1.5 | |
| Cancer (General) | 0.6 | 1 | -0.67 |
| Carcinoma | 4.1 | 2 | 1.05 |
| Celiac Disease | 3.2 | 2.3 | 0.39 |
| Cerebral Palsy | 0.8 | 1 | -0.25 |
| Chronic Fatigue Syndrome | 3.3 | 6.5 | -0.97 |
| Chronic Kidney Disease | 2.8 | 2.3 | 0.22 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.7 | 0.12 |
| Chronic Urticaria (Hives) | 1.6 | 1.2 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 2.9 | 1.3 | 1.23 |
| Colorectal Cancer | 6.5 | 2.5 | 1.6 |
| Constipation | 1.8 | 1.1 | 0.64 |
| Coronary artery disease | 2.6 | 2.7 | -0.04 |
| COVID-19 | 7.3 | 9.7 | -0.33 |
| Crohn's Disease | 8.7 | 5.2 | 0.67 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.1 | 1 | 0.1 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.3 | 1.1 | 2 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 8.5 | 8.1 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 2 | 2.1 | -0.05 |
| Endometriosis | 3.2 | 2 | 0.6 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.7 | 1.5 | 1.47 |
| erectile dysfunction | 2.2 | 2.2 | |
| Fibromyalgia | 2.7 | 2.9 | -0.07 |
| Functional constipation / chronic idiopathic constipation | 5 | 3.1 | 0.61 |
| gallstone disease (gsd) | 3.7 | 0.8 | 3.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 1.1 | 0.91 |
| Generalized anxiety disorder | 3.1 | 1.6 | 0.94 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.8 | 0.5 |
| Graves' disease | 1 | 2.4 | -1.4 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2.4 | 0.9 | 1.67 |
| Heart Failure | 4.5 | 1.3 | 2.46 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 2 | 2 | |
| hypercholesterolemia (High Cholesterol) | 1 | 1 | |
| hyperglycemia | 1.6 | 0.9 | 0.78 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.5 | 4.5 | -0.29 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 3.3 | 0.6 | 4.5 |
| IgA nephropathy (IgAN) | 1.3 | 3.8 | -1.92 |
| Inflammatory Bowel Disease | 8 | 8 | 0 |
| Insomnia | 2.1 | 1.8 | 0.17 |
| Intelligence | 1.9 | 0.6 | 2.17 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 6.1 | 3.8 | 0.61 |
| ischemic stroke | 1.7 | 1.7 | 0 |
| Liver Cirrhosis | 6.7 | 3.3 | 1.03 |
| Long COVID | 6.2 | 6.2 | 0 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.7 | 0.29 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.3 | 4 |
| ME/CFS with IBS | 0.8 | 2.1 | -1.63 |
| ME/CFS without IBS | 1.1 | 2.1 | -0.91 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 7.3 | 6 | 0.22 |
| Mood Disorders | 7.4 | 6.3 | 0.17 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.1 | 6.5 | -0.27 |
| Multiple system atrophy (MSA) | 0.6 | 0.1 | 5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.4 | -2.4 | |
| Neuropathy (all types) | 0.4 | 2.2 | -4.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.1 | 3 | 0.7 |
| NonCeliac Gluten Sensitivity | 0.7 | 0.3 | 1.33 |
| Obesity | 9.1 | 6.6 | 0.38 |
| obsessive-compulsive disorder | 4.8 | 3.4 | 0.41 |
| Osteoarthritis | 2.9 | 0.6 | 3.83 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 2.1 | 0.6 | 2.5 |
| Parkinson's Disease | 6.1 | 7 | -0.15 |
| Polycystic ovary syndrome | 6.6 | 2 | 2.3 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.9 | 1.7 | -0.89 |
| Primary sclerosing cholangitis | 1.5 | 2.8 | -0.87 |
| Psoriasis | 2.9 | 3.4 | -0.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 4.1 | 0.71 |
| Rosacea | 0.7 | -0.7 | |
| Schizophrenia | 5 | 2.2 | 1.27 |
| scoliosis | 0.8 | 0.9 | -0.13 |
| Sjögren syndrome | 2.3 | 2.3 | 0 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 1.9 | |
| Stress / posttraumatic stress disorder | 2.9 | 1.8 | 0.61 |
| Systemic Lupus Erythematosus | 4.3 | 1.9 | 1.26 |
| Tic Disorder | 1.2 | 1.5 | -0.25 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.5 | 2.2 | 1.05 |
| Type 2 Diabetes | 8.1 | 6.5 | 0.25 |
| Ulcerative colitis | 6.1 | 5.9 | 0.03 |
| Unhealthy Ageing | 4.8 | 2.2 | 1.18 |
| Vitiligo | 1.9 | 1.3 | 0.46 |
